At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 415 enrolled
Drug / intervention
MT10109L +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines
In Brief
A Phase 3 clinical trial evaluating MT10109L and Placebo for Glabellar Lines and Lateral Canthal Lines. Completed, enrolled 415 participants across 21 sites in 4 countries.
Detailed Summary
To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Lines, Lateral Canthal Lines
CountriesCanada, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionMar 2020
Study CompletionJan 2021
TodayJul 2026
First PostedOct 26, 2018
Enrollment StartOct 26, 2018
Primary CompletionMar 5, 2020
Study CompletionJan 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.7 years ago
Interventions
MT10109Ldrug
MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Placebodrug
Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.